IDEAYA Biosciences (IDYA) Stock: Buy, Sell, or Hold?
IDYA - IDEAYA Biosciences, Inc. Common Stock
$36.06
-0.05 (-0.14%)
▼
5d:
-5.25%
30d:
-4.07%
90d:
-1.61%
HOLD
MODERATE Confidence
Analysis Updated: Oct 12, 2026 12:00 AM ET
Earnings: Nov 03, 2026
20d
Get Alerted When IDYA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: IDYA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: IDYA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: IDYA is currently trading at $36.06, which is considered oversold relative to its 30-day fair value range of $36.70 to $38.75.
Technical Outlook: Technically, IDYA is in a strong uptrend. The price is currently testing key support at $35.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $52.75 (+46.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, IDYA is in a strong uptrend. The price is currently testing key support at $35.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $52.75 (+46.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$36.70 -
$38.75
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (41/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 46.3% below Wall St target ($52.75)
- NEUTRAL: Bottoming setup forming (41/100) — watch for confirmation
- CAUTION: 5-day price weakness (-5.3%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$36.70 -
$38.75
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$3.24
(9.0%)
Support & Resistance Levels
Support Level
$35.10
Resistance Level
$39.39
Current Trend
Strong Uptrend
Technical data as of
Oct 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.00
Wall Street Target
$52.75
(+46.3%)
Revenue Growth (YoY)
55.4%
Profit Margin
-74.8%
Share & Embed Analysis
Last updated: October 13, 2026 7:10 AM ET
Data refreshes hourly during market hours. Next update: 8:10 AM
Data refreshes hourly during market hours. Next update: 8:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IDYA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
27 analysts |
$92 | 62 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$109 | 70 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$285 | 52 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
17 analysts |
$37 | 64 BUY |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 73 BUY |
